NICE reprieve for Alimera's Iluvien
This article was originally published in Scrip
Executive Summary
Alimera Sciences' Iluvien (fluocinolone acetonide intravitreal implant) is a step away from winning final and binding endorsement from England's health technology appraisal institute, NICE, for the treatment of chronic diabetic macular edema that does not respond to available treatments. The institute has published final draft guidance recommending the drug.